Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study

Progress in Neuro-psychopharmacology & Biological Psychiatry
Simon SurguladzeMichael J Travis

Abstract

The aim of the study was to examine the costs of schizophrenia treatment using the atypical antipsychotic amisulpride relative to treatment with other antipsychotics. Service use data were collected for one year of amisulpride treatment. The patients were also assessed with the Global Assessment of Functioning (GAF) scale and scales of Quality of Life. These were compared with retrospectively collected data for the 1-year period prior to the patients commencing amisulpride. The findings indicate that, compared with the year before, the clinical and quality of life scores improved during the year of treatment with amisulpride. There was a numerical reduction of total costs, as well as costs of in- and out-patient service use per patient per year during the year on amisulpride compared with the year before the patients started amisulpride. Patients on amisulpride spent fewer days as acute in-patients, but stayed longer in rehabilitation wards. Amisulpride treatment may lead to a reduction in the cost of treating schizophrenia in comparison with treatment with other antipsychotic medications.

References

Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Jan 1, 1995·Schizophrenia Bulletin·S M Evers, A J Ament
Aug 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·K J Aitchison, R W Kerwin
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·Martin Knapp
Nov 27, 1998·Arthritis Care and Research : the Official Journal of the Arthritis Health Professions Association·T A CronanM Tomita
Mar 13, 1999·The Journal of Clinical Psychiatry·G S Sachs, S Gaughan
Aug 24, 2006·Expert Opinion on Pharmacotherapy·Barrat Luft, David Taylor
Mar 29, 2008·Clinical Drug Investigation·S MorrisA McGuire

Citations

May 29, 2009·Cost Effectiveness and Resource Allocation : C/E·Douglas E FariesHaya Ascher-Svanum
Jun 27, 2009·Neuropsychiatric Disease and Treatment·Ann Mortimer
Feb 4, 2010·Current Medical Research and Opinion·Philippe Nuss, Cedric Tessier

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here